43.10 0.00 (0.00%)
After hours: 5:01PM EDT
|Bid||43.12 x 800|
|Ask||43.19 x 1100|
|Day's Range||42.69 - 43.49|
|52 Week Range||37.01 - 59.59|
|Beta (3Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.92|
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
Acceleron stock rebounded Tuesday after the biotech company scrapped a rare muscular dystrophy treatment that failed in Phase 2 testing. Patients' muscles grew, but function didn't improve.
The company said it was discontinuing development of an experimental drug meant to treat facioscapulohumeral muscular dystrophy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder ...
Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type of muscular dystrophy showed no evidence of benefits relative to a placebo. The company has stopped further clinical trials, saying it was "disappointed" with the results. The treatment, called ACE-083, is on a trial for another neuromuscular disorder and topline results are expected in the first quarter, Acceleron said. The stock ended the regular trading day 1.7% higher.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial. As a result, Acceleron will not conduct further clinical trials of ACE-083 in FSHD.
The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.
Cambridge, Massachusetts-based Acceleron Pharma Inc (NASDAQ: XLRN ) said Monday that the FDA has accorded Orphan Drug Designation to its sotatercept. The drug is an investigational asset to treat pulmonary ...
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH). “We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
In 2016 Habib Dable was appointed CEO of Acceleron Pharma Inc. (NASDAQ:XLRN). This report will, first, examine the CEO...
Acceleron (XLRN) delivered earnings and revenue surprises of -41.67% and 1.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Age
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the urgency for new therapeutic options for patients with PAH,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron.